Boehringer Ingelheim and Bayer HealthCare Extend Commercial Production Agreement for Betaferon®

Boehringer Ingelheim is pleased to announce the US-registration for manufacturing of Bayer HealthCare’s Betaferon® against multiple sclerosis. Recently Bayer HealthCare has extended the commercial production agreement for Betaferon with Boehringer Ingelheim, which received the FDA approval for Betaferon (US brand name: Betaseron®) on 2 May 2011. The focus of the strategic partnership between the two companies is to establish Boehringer Ingelheim as the global supplier for Betaferon. The manufacturing approval for the US market is a very important milestone within this partnership.

The agreement covers manufacturing (in Vienna, Austria) and fill and finish (in Biberach, Germany) at Boehringer Ingelheim’s large-scale facilities. In 1995 Boehringer Ingelheim started as contract manufacturer of Betaferon for the European market.

“We are pleased to extend our longstanding and successful relationship with Bayer HealthCare,” stated Simon Sturge, corporate senior vice president biopharmaceuticals. “Boehringer Ingelheim is well prepared to meet the global market demands for Betaferon.”

More About This Company